91
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: a preliminary study

, , , &
Pages 541-557 | Received 12 Jan 2007, Published online: 08 Oct 2008

References

  • Adams MR, Sears R, Nuckolls F, Leone G, Nevins J. Complex transcription regulatory mechanisms control expression of the E2F3 locus. Molecular and Cellular Biology 2000; 20: 3633–3639
  • Andersen CL, Jensen JL, Ørntoft TF. Normalisation of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalisation, applied to bladder and colon cancer data sets. Cancer Research 2004; 64: 5245–5250
  • Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on solid tumour prognostic factors and the 1999 World Health Organization second international consultation on prostate cancer. Seminars in Urologic Oncology 1999; 17: 222–272
  • Brawer MK. Prostate-specific antigen. Seminars in Surgical Oncology 2000; 18: 3–9
  • Bustin SA. Absolute quantification of mRNA using real-time reverse-transcription polymerase chain reaction assays. Journal of Molecular Endocrinology 2000; 25: 169–193
  • Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. Journal of Biomolecular Techniques 2004; 15: 155–166
  • Dearnaley DP, Kirby RS, Kirk D, Malone P, Simpson RJ, Williams G. Diagnosis and management of early prostate cancer. Report of a British Association of Urological Surgeons Working Party. British Journal of Urology 1999; 83: 18–33
  • DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochimica et Biophysica Acta 2002; 1602: 131–150
  • DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361: 955–964
  • Eder IE, Bektic J, Haag P, Bartsch G, Klocker H. Genes differentially expressed in prostate cancer. British Journal of Urology 2004; 93: 1151–1155
  • Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R, Foster CS, Cooper CS. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004; 23: 1627–1630
  • Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004; 23: 5871–5879
  • Ghossein RA, Bhattacharya S, Coit DG. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of melanoma-related transcripts in the peripheral blood and bone marrow of patients with malignant melanoma. What have we learned? Recent Results. Cancer Research 2001; 158: 63–77
  • Ginzinger DG. Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Experimental Haematology 2002; 30: 503–512
  • Grönberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859–864
  • Hampton R, Walker M, Marshall J, Juhl H. Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells. Oncogene 2002; 21: 7817–7823
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70
  • Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573–582
  • Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, Humphrey PA, Roehl KA, Catalona WJ. Prostate-specific antigen cut-off of 2.6 ng/ml for prostate cancer screening is associated with favourable pathologic tumour features. Urology 2002; 60: 469–473
  • Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003; 62(Supplement 6B)19–35
  • Latchman D. 1998. Gene Regulation: a eukaryotic perspective. UK: Stanley Thornes Ltd, 304–305.
  • McIntyre IG, Spreckley K, Clarke RB, Anderson E, Clarke NW, George NJ. Optimization of the reverse transcriptase polymerase chain reaction for the detection of circulating prostate cells. British Journal of Cancer 2000; 83: 992–997
  • Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 1998; 24: 954–962
  • Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation and apoptosis. Genes and Development 2001; 15: 267–285
  • Nelson WG, De Marzo AM, Isaacs WB. Mechanisms of disease: prostate cancer. New England Journal of Medicine 2003; 349: 366–381
  • Nevin JR. Towards an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth and Differentiation 1998; 9: 585–593
  • Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ, Sauter G. E2F3 amplification and overexpression is associated with invasive tumour growth and rapid tumour cell proliferation in urinary bladder cancer. Oncogene 2004; 23: 5616–5623
  • O'Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG, Terstappen LW. Multigene reverse transcription-PCR profiling of circulating tumour cells in hormone-refractory prostate cancer. Clinical Chemistry 2004; 50: 826–835
  • Ohl F, Junf M, Xu C, Stephan C, Rabien A, Burkhardt M, Nitsche A, Kristiansen G, Loening SA, Radonic A, Jung K. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?. Journal of Molecular Medicine 2005; 83: 1014–1024
  • Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. European Journal of Cancer 2001; 37: S4–66
  • Pfaffl MW. 2004. Quantification strategies in real-time PCR. In: Bustin SAA–Z of quantitative PCR. La JollaCA, USA: International University Line, Chapter 3.
  • Rasmussen R. Quantification on the LightCycler. Rapid Cycle Real-time PCR, Methods and Applications, S Meuer, C Wittwer, K Nakagawara. Springer Press, Heidelberg 2001; 21–34
  • Roche Applied Science Technical Note No. LC 13/2001: Relative Quantification.
  • Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. Journal of Urology 1993; 150: 379–385
  • Schott A, Vogel I, Krueger U, Kalthoff H, Schreiber HW, Schmiegel W, Henne-Bruns D, Kremer B, Juhl H. Isolated tumour cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Annals of Surgery 1998; 227: 372–379
  • Szabo A, Perou CM, Karaca M, Perreard L, Quackenbush JF, Bernard PS. Statistical modelling for selecting housekeeper genes. Genome Biology 2004; 5: R59.1–R59.10
  • Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624–629
  • Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M. Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. Physiological Genomics 2000; 2: 143–147
  • Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Jr, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Research 2001; 61: 5974–5978

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.